Jade Biosciences (JBIO) news
Recent news
Jade Biosciences: Phase 1 trial for Jade301 to begin in Q4 2026; interim data in H2 2027
Jade Biosciences (JBIO) announced that its Phase 1 clinical trial for JADE301, a half-life–extended, subcutaneous anti–IFN-β candidate for dermatomyositis, is expected to begin in the fourth quarter of 2026. Interim data from the trial is anticipated in the second half of 2027. The company also…
AInvest Wire · Sep 30, 2026Jade Biosciences, - Jade301 well tolerated in non-human primates at all subcutaneous doses
AInvest Wire · Sep 30, 2026Jade Biosciences, - Jade301 shows about 25-day half-life and predictable muscle distribution in primates
AInvest Wire · Sep 30, 2026Jade Biosciences, - Jade301 demonstrates high-affinity, selective IFN-β binding and greater potency than Dazukibart
AInvest Wire · Sep 30, 2026Jade Biosciences, Inc.: Clear Street raises target price to $48 from $25
Jade Biosciences, Inc. (NASDAQ: JBio) has seen a notable increase in its stock price, rising $2.64, or 15.70% , since the previous market close, with shares opening at $17.90. The company, which focuses on developing therapies for rare cardiopulmonary and autoimmune diseases, has drawn attention…
AInvest Wire · Sep 4, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.